5 Stocks Moving The Drugs Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 4 points (0.0%) at 15,449 as of Wednesday, Feb. 5, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 771 issues advancing vs. 2,156 declining with 142 unchanged.

The Drugs industry currently sits down 1.6% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include Grifols ( GRFS), down 4.6%, Regeneron Pharmaceuticals ( REGN), down 2.2% and Valeant Pharmaceuticals International ( VRX), down 1.5%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Novo Nordisk A/S ( NVO) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novo Nordisk A/S is up $1.39 (3.5%) to $40.97 on average volume. Thus far, 1.1 million shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $40.34-$40.98 after having opened the day at $40.39 as compared to the previous trading day's close of $39.58.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $91.7 billion and is part of the health care sector. Shares are up 7.1% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, good cash flow from operations and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Novo Nordisk A/S Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Shire ( SHPG) is up $2.45 (1.7%) to $150.26 on average volume. Thus far, 312,790 shares of Shire exchanged hands as compared to its average daily volume of 424,300 shares. The stock has ranged in price between $149.88-$151.35 after having opened the day at $151.11 as compared to the previous trading day's close of $147.81.

Shire plc, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $27.4 billion and is part of the health care sector. Shares are up 3.4% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts who rate Shire a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Shire Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, GlaxoSmithKline ( GSK) is up $0.61 (1.2%) to $51.51 on heavy volume. Thus far, 2.1 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $51.11-$51.55 after having opened the day at $51.54 as compared to the previous trading day's close of $50.90.

GlaxoSmithKline plc manufactures and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $123.8 billion and is part of the health care sector. Shares are down 4.5% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates GlaxoSmithKline a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, increase in stock price during the past year, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Merck ( MRK) is up $0.35 (0.7%) to $53.86 on heavy volume. Thus far, 13.3 million shares of Merck exchanged hands as compared to its average daily volume of 12.5 million shares. The stock has ranged in price between $53.42-$55.20 after having opened the day at $54.28 as compared to the previous trading day's close of $53.51.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $152.2 billion and is part of the health care sector. Shares are up 6.9% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts who rate Merck a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Johnson & Johnson ( JNJ) is up $0.77 (0.9%) to $87.39 on average volume. Thus far, 4.4 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 7.9 million shares. The stock has ranged in price between $86.48-$87.67 after having opened the day at $86.52 as compared to the previous trading day's close of $86.62.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $244.8 billion and is part of the health care sector. Shares are down 5.4% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).
null

If you liked this article you might like

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade

Novo Nordisk Shares Leap Higher After Solid Earnings and Full-Year Sales Upgrade